Clinical trials: Paclitaxel, completed
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00729612
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Greg Otterson
Breast Cancer
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Vorinostat is a histone deacetylase (HDAC) inhibitor which is approved by the U.S. Food and Drug Administration for the treatment of a rare type of cancer involving the skin (cutaneous T cell lymphoma), but not for breast cancer.
- Trial name
- NCT00574587
- Testing
- Vorinostat, Paclitaxel, Trastuzumab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Cancer
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in…
- Trial name
- NCT03989336
- Testing
- Manganese Chloride, nab-paclitaxel, Platinum chemotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Multicenter, open label, non-randomized phase 2 trial to evaluate the efficacy and safety of nab-paclitaxel in the neoadjuvant treatment of ER positive human epidermal growth factor receptor 2 (HER2) negative patients amenable to…
- Trial name
- NCT01565499
- Testing
- Nab-paclitaxel
- Where
- 13 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease
Safety and Efficacy Registry of Yinyi Stent
Drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. Persistent polymer could be responsible.
- Trial name
- SERY-I (NCT01373645)
- Testing
- Yinyi stent
- Where
- China
- Volunteers
- 1,045 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
HEAD & NECK Cancer
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
For patients with this type of cancer, one standard treatment option is cetuximab (Erbitux®) + radiation. We wish to study the addition of albumin-bound paclitaxel (Abraxane®) to this standard regimen of cetuximab + radiation.
- Trial name
- NCT00736619
- Testing
- Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Breast Cancer
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer.
- Trial name
- NCT00546156
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ian E. Krop, MD, PhD
Stable Angina, Unstable Angina
Drug Coated Balloon Compared to Bare Metal Stent for de Novo Coronary Artery Lesions
This randomized trial will assess the efficacy of Drug Coated Balloon (DCB) compared to Bare Metal Stent (BMS) using Fractional Flow Reserve (FFR) guidance for de novo coronary artery lesions in patients unable to tolerate dual…
- Trial name
- NCT02456402
- Testing
- Drug Coated Balloon, Bare Metal Stent
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Ulsan University Hospital
Advanced Pancreatic Cancer
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.
- Trial name
- NCT01010945
- Testing
- erlotinib, gemcitabine, nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- OSI Pharmaceuticals
Advanced Solid Tumors
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
- Trial name
- NCT02057380
- Testing
- linsitinib, erlotinib, paclitaxel
- Where
- 12 sites in United States, Brazil and 5 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients diagnosed with…
- Trial name
- NCT03283761
- Testing
- Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Al B. Benson, III, MD
Advanced Non Small Cell Lung Cancer
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
Lung cancer is the most common cancer in the world and the leading cause of cancer-related deaths in Western countries. Unfortunately, at the time of diagnosis, the majority of patients already have metastatic disease and a…
- Trial name
- eNERGY (NCT03351361)
- Testing
- Nivolumab + Ipilimumab, Chemotherapy
- Where
- 30 sites in France
- Volunteers
- 217 people
- Sponsor
- Rennes University Hospital
GastroEsophageal Cancer
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer.
- Trial name
- NCT03279237
- Testing
- Irinotecan, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Carcinosarcoma, Ovarian
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
- Trial name
- NCT03206177
- Testing
- Galunisertib, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Oklahoma
Small Cell Lung Cancer
Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer
The objective of this phase I study is to determine the maximum tolerated dose (MTD) of combination therapy of paclitaxel and everolimus in small cell lung cancer patient with previous treatment history.
- Trial name
- NCT01079481
- Testing
- taxol plus everolimus
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Samsung Medical Center
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV)…
- Trial name
- NCT00951665
- Testing
- paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Genentech, Inc.
HER2-negative Breast Cancer, HER2-positive Breast Cancer
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic.
- Conditions
- HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00003440
- Testing
- paclitaxel, trastuzumab, quality-of-life assessment
- Where
- United States
- Volunteers
- 580 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT03056833
- Testing
- ribociclib, Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ronald Buckanovich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.